PathAI, an international frontrunner in artificial intelligence (AI)-powered technology for pathology, and Cleveland Clinic declared a five-year strategic collaboration that will concentrate on leveraging PathAI’s quantitative pathology algorithms to perform new translational studies and for application as clinical diagnostics in different areas of diseases.
This cooperative effort merges PathAI’s AI-based platforms with Cleveland Clinic’s clinical proficiency and multi-modal data to unravel a wide implementation of future pathology diagnostics.
Our commitment is to provide the best possible care for our patients, and it is increasingly clear that AI-powered pathology can radically enhance diagnostic accuracy and treatment selection. By doing this work, we’re able to maximize the value of machine learning for our patients and fuel deeper innovation that can result in better outcomes.
Dr. Brian Rubin, Chair, Pathology and Laboratory Medicine Institute, Cleveland Clinic
The digitization of several pathology specimens will be enabled by the association, forming millions of whole slide images through areas of multiple diseases. Cleveland Clinic and PathAI will have an enriched multi-modal dataset to perform the study with PathAI’s technology platform and pathology algorithms’ menu by linking the digital pathology data with clinical and molecular data.
Educational opportunities will also be provided by this partnership for Cleveland Clinic faculty and trainees, with an aim of allowing the design and usage of AI-driven pathology diagnostics to enhance patient care. As part of this agreement, Cleveland Clinic will become an equity holder in PathAI.
PathAI will get entry to the digitized pathology slides to develop and enhance its AI-driven algorithms, alongside clinical data for research and evaluation purposes — all of them have been de-identified to protect the patients’ privacy. To guarantee algorithms are fit for purpose, in clinical as well as research settings, Cleveland Clinic’s medical team will offer its expertise.
This exciting collaboration accelerates PathAI’s mission to provide precision pathology for everyone. Cleveland Clinic is the ideal partner, with its many leading clinicians, educators, and researchers who are committed to transforming patient care across disease areas.
Dr. Andy Beck, CEO, PathAI
“We see an incredible opportunity to accelerate innovation in precision pathology and to use our strengths to bridge communities in the healthcare ecosystem including patients, biopharma, and academic research,” concludes Dr. Andy Beck.